Catalogue Number: AB03056-15.0-BT-ABA
| Manufacturer: | Vector Laboratories, Inc (ABA) |
| Type: | Recombinant Monoclonal |
| Alias: | gD; Envelope glycoprotein D |
| Shipping Condition: | Blue Ice |
| Unit(s): | 500 ug |
| Host name: | Human |
| Clone: | HSV8 |
| Isotype: | IgM |
| Immunogen: | The original antibody was derived from a human antibody library displayed on phage, and identified by panning with herpes simplex virus proteins. |
| Application: | ELISA, IF, IP, WB, NT, Inh, InVivoA |
Purified
Recombinant Monoclonal
2703444
US6
Q69091
Store at 4⁰C for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommed this antibody be handled under sterile conditions. For longer storage, aliquot and store at -20⁰C.
Screening of the phage display for significant binding towards HSV-1 and HSV-2 was done using ELISA; The Fab supernates were tested in immunofluorescence studies with virus infected cells. The protein recognized by the Fab was identified via immunoprecipitation. Western blot confirmed specificity Fab for gD. Fab fragment neutralizes infectivity and prevents cell-to-cell transmission of herpes simplex viruses 1 and 2. The Fab fragment neutralized HSV-1 at 0.25 ug/ml (50% reduction) and HSV-2 at 0.05 ug/ml. This Fab also inhibited plaque formation when applied to virus-infected monolayers, completely abolishing HSV-2 plaque development at 25 ug/ml 72 hours postinfection, indicating the ability of the Fab to prevent cell-to-cell spread of virus (Burioni et al, 1994; PMID:8278393). In vivo experiments showed that the antibody (IgG1) reduced the mortality rate in mice when administrated before HSV type 1 infection and it prolonged survival times when administered up to 24 hours postinfection (Sanna et al, 1996; PMID:8553581). The epitope mapping of this antibody was done using competition ELISA. The antibody demonstrated potent activities against cell-associated virus in a syncytium inhibition assay (De Logu et al, 1998; PMID:9774565). IgG1, Fab and F(ab)2 fragments were tested against HSV-2 in mice in vivo and they were approximately equally protective (Zeitlin et al, 1996; PMID:8918548).
This reformatted human antibody was made using the variable domain sequences of the original Human Fab format for improved compatibility with existing reagents assays and techniques.